Diabetes Drug Restriction Should Be Eased, US Panel
Experts urged the US federal to reduce the restrictions imposed on GlaxoSmithKline's controversial diabetes drug Avandia
Experts urged the US federal to reduce the restrictions imposed on GlaxoSmithKline's controversial diabetes drug Avandia
‘The diabetes drug, metformin allows more oxygen to be released into the cells, which boosts health, increases energy and lifespan.’
Tweet it Now
"If you target an aging process and you slow down aging then you slow down all the diseases and pathology of aging as well," said aging expert Prof Gordon Lithgow, of the Buck Institute for Research on Aging in California, and one of the study advisers. Researchers have already proven that the diabetes drug metformin extends the life of animals. Now experts want to see if the same effects can be replicated in humans.
Last year researchers at Cardiff University found that when patients with diabetes were given the drug they lived longer than others without the condition, even though they should have died eight years earlier on average. The trials are expected to take five to seven years.
After Cancer, Diabetes Drug may Not Improve Survival Rates
Despite previous scientific studies that suggest diabetes drug metformin has anti-cancer properties, a new study has found that the drug may not improve survival rates after breast cancer.
Despite previous scientific studies that suggest diabetes drug metformin has anti-cancer properties, a new study has found that the drug may not improve survival rates after breast cancer.
Source-ANI
Diabetes Drug Tested in Patients With Parkinson's Disease
A degenerative neurological disorder marked by a progressive loss of motor control is Parkinson's disease (PD).
A degenerative neurological disorder marked by a progressive loss of motor control is Parkinson's disease (PD).
Diabetes Drug 'Could Double' Pancreatic Cancer Risk: Researchers
Medication known as incretin mimetics could double the risk of developing pancreatic cancer, according to researchers.
Medication known as incretin mimetics could double the risk of developing pancreatic cancer, according to researchers.
